94 results about "Fusobacteria" patented technology

The invention provides a nano-drug based on atomic layer deposition and a preparation method of the nano-drug, mesoporous silica is taken as a carrier, bimetallic nanoparticles are precisely deposited through ALD, and chemotherapeutic drugs and antibacterial components are loaded by combining amination and targeted PEG modification, so that the following functions are realized: (1) H2O2 in a tumor microenvironment is catalyzed to generate reactive oxygen species (ROS); removing fusobacterium nucleatum and damaging a biological membrane of the fusobacterium nucleatum; (2) GSH is consumed through Fenton reaction, and tumor drug resistance is reversed; and (3) the drug is released in pH response, and tumor cells are accurately killed. The invention further provides application of the nano-drug based on atomic layer deposition in treatment of related drug-resistant colorectal cancer induced by fusobacterium nucleatum, the process is controllable, the biocompatibility is excellent, the treatment effect on the drug-resistant colorectal cancer is remarkably improved, and the nano-drug has wide clinical application prospects.

The invention belongs to the technical field of biology, and particularly relates to a construction method and application of a model with fusobacterium nucleatum damaged mouse intestinal tract organoid, and the construction method comprises the following steps: separating mouse intestinal tract organoid; obtaining a culture supernatant with fusobacterium nucleatum; obtaining a cell-free extract with fusobacterium nucleatum; viable bacteria with fusobacterium nucleatum are obtained; and treating the mouse intestinal organ with the fusobacterium nucleatum culture supernatant or the fusobacterium nucleatum cell-free extract or the fusobacterium nucleatum viable bacteria to obtain the model of the mouse intestinal organ damaged by the fusobacterium nucleatum. The construction method of the organ-like model with the fusobacterium nucleatum damaged intestinal tract is simple, operability and convenience can be increased for further research on a regulation mechanism of the fusobacterium nucleatum damaged intestinal tract, and a reliable and accurate research tool is provided for gastrointestinal diseases such as inflammatory bowel diseases and colorectal cancer.

The invention relates to an mRNA (messenger Ribonucleic Acid) vaccine targeting FomA and application of the mRNA vaccine in immunotherapy of esophageal squamous carcinoma in the technical field of tumor immunotherapy. The problems that in the prior art, a specific targeting vaccine for the fusobacterium nucleatum membrane protein FomA lacks, traditional antibiotics can only kill extracellular bacteria and cannot remove intracellular colonized fusobacterium nucleatum, and cellular immunity cannot be effectively activated to remove fusobacterium nucleatum colonized in tumor tissue; the immunotherapy drug resistance of esophageal squamous carcinoma caused by fusobacterium nucleatum infection is difficult to reverse. According to the technical scheme, an mRNA molecule with a fusobacterium nucleatum FomA extracellular domain tandem repeat sequence and a lipid nanoparticle delivery system are coded, an extramembrane segment tandem repeat immune enhancement technology is adopted for design, two extracellular ring sequences are repeated for 2-5 times and connected through a connector sequence, lipid nanoparticles are composed of optimized quaternary lipids, and the lipid nanoparticles are prepared from the quaternary lipids. And a PD-1 monoclonal antibody is combined to activate FomA specific CD8 + T cell immunoreaction, so that comprehensive removal of intracellular and extracellular bacteria and bacteria targeted immune remodeling are realized.

The invention relates to the technical field of biological detection, and particularly discloses a microbial marker combination for predicting neoadjuvant chemotherapy sensitivity of colorectal cancer and application of the microbial marker combination, and the microbial marker combination comprises treponema, staphylococcus, streptococcus, facultative diplococcus and fusobacterium. The invention further discloses a method for predicting the neoadjuvant chemotherapy sensitivity of colorectal cancer and application of the microbial marker combination for predicting the neoadjuvant chemotherapy sensitivity of colorectal cancer and application of the microbial marker combination for predicting the neoadjuvant chemotherapy sensitivity of colorectal cancer, and the microbial marker combination comprises treponema, staphylococcus, streptococcus, facultative diplococcus and fusobacterium. According to the application, by analyzing the microbial community composition in the tumor microenvironment of the colorectal cancer patient, the microbial marker related to the neoadjuvant chemotherapy sensitivity is identified, the patient insensitive to neoadjuvant chemotherapy can be accurately predicted based on the microbial marker combination disclosed in the application, the treatment risk is reduced, the invalid treatment is reduced, and the treatment effect is improved. And a reliable basis is provided for formulating precise personalized treatment.

The invention discloses application of macrophage exosome molecules induced by fusobacterium nucleatum, and belongs to the technical field of molecular biology. The nucleotide sequence of the macrophage exosome molecule induced by fusobacterium nucleatum is 5 '-ACUGGCUAGGGAAAAUGAUUGGAU-3', and the macrophage exosome molecule can be applied to preparation of a preparation for inducing VSMC cells to be converted into macrophage-like phenotypes, can regulate and control the atherosclerosis process, and provides a new thought and theoretical basis for further research of exosome in the atherosclerosis progress process.

The invention relates to the field of tumor immunotherapy, in particular to an mRNA vaccine targeting fusobacterium nucleatum membrane protein FomA and application of the mRNA vaccine in esophageal squamous cell carcinoma immunotherapy. The vaccine comprises a nucleotide sequence for coding a specific epitope of FomA, and the specific epitope contains 1-10'GGSGGGGSGG 'repetitive sequences and has homology gt in different strains; 95%. The mRNA is encapsulated in lipid nanoparticles (the particle size is 80-150 nm, the polydispersity coefficient is lt; and the liposome is composed of 38-42% of cationic lipid, 18-22% of neutral lipid, 33-37% of cholesterol and 3-5% of PEG modified lipid, and the encapsulation efficiency is 85-95%. The vaccine can specifically reduce the abundance of fusobacterium in tumors by 72.4 + / -8.0%, the tumor microenvironment is converted into an immune activation type, and the proportion of CD8 + T cells is increased from 5.2 + / -1.0% to 14.5 + / -2.0%. When the compound is combined with a PD-1 inhibitor, the objective remission rate reaches 70%, the tumor volume is reduced by 78.5 + / -8.0%, and the compound is suitable for treating clostridium-enriched esophageal squamous carcinoma.

The invention discloses composite yolk immunoglobulin antibody toothpaste and a preparation method thereof, and the toothpaste comprises the following components in percentage by mass: 0.01-1.0% of yolk immunoglobulin; 10-70% of a humectant; 0.01%-0.5% of an acid-base buffer agent; 0.01%-0.5% of a taste improver; 0.1%-3% of a thickening agent; 5-50% of a friction agent; 0.1-5% of a foaming agent; 0.01%-0.5% of an appearance improver; 0.1 to 2.0 percent of essence; and the balance of water. Wherein the egg yolk immune globulin is a composite specific egg yolk antibody for resisting porphyromonas gingivalis, fusobacterium nucleatum and prevotella intermedia. Starting from three key pathogenic bacteria causing periodontal diseases, the egg yolk composite antibody resisting porphyromonas gingivalis and having specificity of fusobacterium nucleatum and prevotella intermedius is added into a toothpaste formula, and the effects of inhibiting bacteria, preventing and relieving oral inflammation, repairing gingiva and the like are achieved in a tooth brushing mode.

The invention provides a nano medicinal preparation for tumor treatment as well as a preparation method and application thereof, and relates to the technical field of medicinal preparations. The preparation method of the nano medicinal preparation comprises the following steps: S1, adding metal salt and oxidase into water, uniformly stirring and mixing to form a compound, then adding antibiotics, and continuously stirring and uniformly mixing for reaction to obtain a mixed solution; and S2, centrifuging the mixed solution, collecting the precipitate, washing, and dispersing into water for storage to obtain the nano-drug preparation. The nano medicinal preparation disclosed by the invention can intelligently respond to a tumor microenvironment, efficiently remove fusobacterium nucleatum in tumors and kill tumor cells through synergistic antibacterial and anticancer effects, so that tumor development is inhibited. Moreover, the complex prepared by the invention can enhance the stability of a medicinal preparation, can realize targeted release of the medicine in a tumor microenvironment, and improves the action effect.

The present invention addresses the problem of providing a composition for controlling bacteria belonging to the genus Fusobacterium among the intestinal flora. The present invention provides a composition for controlling a bacterium belonging to the genus Fusobacterium in the intestinal flora, the composition comprising a bacterium belonging to the family Lactobacillus. The bacterium belonging to the genus fusobacterium is preferably a fusobacterium nucleatum (fusobacterium nucleatum), and the bacterium belonging to the genus fusobacterium is preferably a fusobacterium nucleatum (fusobacterium nucleatum). It is preferable that the bacterium belonging to the family Lactobacillus belong to a bacterium belonging to any genus selected from the group consisting of the genus Lactobacillus, the genus Lactobacillus, the genus Limosilbacilli, the genus Liiilbacilli, the genus Lactobacillus lactis, the genus Lactobacillus casei, and the genus Lactobacillus plantarum, and that the bacterium belonging to the family Lactobacillus is a bacterium belonging to any genus selected from the group consisting of the genus Lactobacillus, the genus Lactobacillus lactis, the genus Lactobacillus acidophilus, the genus Lactobacillus acidophilus, the genus Lactobacillus acidophilus, the genus Lactobacillus acidophilus, the genus Lactobacillus acidophilus and the genus Lactobacillus acidophilus.

The invention belongs to the field of biological medicine, and particularly relates to a fusobacterium nucleatum FtsZ protease inhibitor and application thereof. On the basis of the idea of new use of old drugs, drugs approved by FDA are subjected to structure-based virtual screening and molecular dynamics simulation, and sorafenib, ponatinib, ceritinib and ibastine can be stably combined to active sites of fusobacterium nucleatum FtsZ protease; in-vitro experiments also show that sorafenib, ponatinib, ceritinib and ibastine are inhibitors with the fusobacterium nucleatum FtsZ protease, so that new antibacterial applications of sorafenib, ponatinib, ceritinib and ibastine are explored. The invention not only provides a new angle for antibiotic discovery, but also provides an example for rapid development of a novel FtsZ protease inhibitor.

The present disclosure discloses a strain of Lactobacillus fermentum capable of preventing and / or treating periodontitis and an application thereof, belonging to the field of microbiology technology. The present disclosure has screened to obtain a strain of L. fermentum CCFM1139. The L. fermentum CCFM1139 can alleviate periodontitis by inhibiting formation of mixed bacterial biofilms of Porphyromonas gingivalis, Prevotella intermedia and Fusobacterium nucleatum, thereby reducing the amount of biofilm by 52.45%, and can reduce the content of TNF-α from 131.37 pg / mL to 83.31 pg / mL and IL-8 from 147.70 pg / mL to 121.12 pg / mL in a periodontitis cell model, reduce colonization of the P. gingivalis and the F. nucleatum in the oral cavity by 1-2 orders of magnitude, and reduce the amount of the alveolar bone resorption from 1838.0 μm to 805.7 μm.

The application belongs to the field of chemical biology, and relates to a Fusobacterium nucleatum single-stranded DNA aptamer and a screening method and kit. The nucleotide sequence of the aptamer is as follows: 5'-TGACTGACGACGACTCCGCX1GX2X3X4GX5AGX6X7X8X9X 10 CGTX 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 X 20 X 21 X 22 X 23 GX 24 X 25 X26X 27 X 28 AX 29 X 30 GX 31 X 32 X 33 X 34 X 35 X 36 AGACTGCTCGAGCTG-3'. The aptamer obtained by the application has the characteristics of simple operation, high sensitivity, low manufacturing cost and strong specificity, and has a broad application prospect in the detection of Fusobacterium nucleatum.

This invention discloses a composite nanodelivery system encapsulated in a fusion membrane, its preparation method, and its applications. The nanodelivery system comprises a Ti3C2 / TiO2 / CuInS2 composite material, oxaliplatin loaded thereon, and a fusion membrane encapsulating the outer layer; the fusion membrane is formed by the fusion of Fusobacterium nucleatum extravesicles and M1 macrophage membranes. This invention also discloses a method for preparing the nanodelivery system, including the steps of preparing the Ti3C2 / TiO2 / CuInS2 composite material, preparing the fusion membrane, loading oxaliplatin, and encapsulating it in the fusion membrane. The nanodelivery system prepared by this invention exhibits pH-responsive drug release characteristics, generating H2S in the tumor microenvironment and H2 under light irradiation, while also possessing photocatalytic activity. This invention combines chemotherapy, photoelectrocatalytic therapy, and the regulation of multiple active substances, and can be used to prepare drugs for treating malignant tumors of the digestive system.

The invention discloses a novel fusobacterium strain Fusobacteria sp.HPSCC05 and an application of the novel fusobacterium strain Fusobacteria sp.HPSCC05. The preservation number of the novel fusobacterium strain Fusobacteria sp.HPSCC05 is CCTCC (China Center For Type Culture Collection) NO: M2025588. According to the invention, Fusobacterium sp.HPSCC05 derived from hypopharyngeal squamous cell carcinoma tissues is successfully separated, the strain has key technical attributes of stable growth, repeatable culture, clear preservation conditions and the like, and the problem of deficiency of current hypopharyngeal carcinoma related strains is solved. Fusobacteria sp.HPSCC05 is identified as a new fusobacterium species, and the blank of hypopharyngeal carcinoma tumor ecological niche specific strain resources is filled up. The method comprises the following steps: establishing an in-vitro verification model (fusobacterium-hypopharyngeal squamous carcinoma cell co-culture model) of the hypopharyngeal carcinoma promoting effect of the Fusobacterium sp.HPSCC05, and providing a replicable culture mode;

Peptides for use in systems that prevent the interaction of the FadA protein released from the Fusobacterium nucleatum (F. nucleatum) bacterium with E-cadherin, which has a carcinogenic effect, or the inhibition of the microorganism with antimicrobial agents and that will inhibit the carcinogenesis mechanisms of F. nucleatum infection and enable the development of therapeutic systems against infections that may occur due to the decreased immunity of patients undergoing cancer treatment with the use of peptides with anti-cancer and antimicrobial properties by developing ten peptides with FadA protein binding energy greater than −11.6 kcal / mol. Peptides with anticancer and antimicrobial properties allow the development of therapeutic systems to prevent F. nucleatum infection, to prevent cancer development after F. nucleatum infection, or to develop therapeutic systems against infections that occur due to the decreased immunity of cancer patients due to cancer treatment.

To provide a citrulline-reducing agent for intraoral use.SOLUTION: The present invention provides a citrulline-reducing agent for intraoral use that contains vitamin B6. The citrulline-reducing agent for intraoral use inhibits citrulline production and / or secretion by intraoral bacteria such as those belonging to Porphyromonas, Fusobacterium, Prevotella, Veillonella, Treponema, or Streptococcus.SELECTED DRAWING: None

To provide honey that has higher antibacterial activity to at least one kind of bacterium selected from the group consisting of Fusobacterium nucleatum, Porphyromonas gingivalis and Prevotella intermedia.SOLUTION: A periodontal disease preventive and / or foul breath preventive contain acacia honey and / or honeydew honey as an active ingredient.SELECTED DRAWING: None

The invention discloses an antibacterial peptide and application thereof in preventing and treating dental plaque and gingival problems, and belongs to the technical field of biology. According to the invention, two cationic antibacterial peptides LR18 and LR18-2 with amphiphilic alpha-helical structures are designed from the beginning. The two antibacterial peptides have good antibacterial and bactericidal activity on oral periodontal pathogenic bacteria (including fusobacterium nucleatum, porphyromonas gingivalis and streptococcus mutans), the minimum inhibitory concentration (MIC) is 62.5-500 [mu] g / mL, and the minimum bactericidal concentration (MBC) is 62.5-2000 [mu] g / mL. The structure is simple, the chemical synthesis difficulty is low, a high-purity product can be directly synthesized, the cell hemolytic activity is low, the safety is high, the product can be used for preparing oral antibacterial drugs and / or oral care products, and oral diseases are prevented and treated by inhibiting the growth of oral periodontal pathogenic bacteria.

The invention belongs to the technical field of biology, and discloses a polypeptide with broad-spectrum antibacterial activity and a preparation method and application thereof. The antibacterial peptide or the salt thereof is disclosed for the first time, the antibacterial peptide has a good antibacterial effect on common pathogenic bacteria (such as staphylococcus aureus, escherichia coli, salmonella enteritidis and streptococcus suis) and oral pathogenic bacteria (such as fusobacterium nucleatum and porphyromonas gingivalis), and the antibacterial peptide shows slight cytotoxicity on mammalian cells only under high concentration; and the safety is relatively high.

The invention discloses a preparation method for constructing a mouse embryo implantation failure model based on fusobacterium variabilis, and belongs to the technical field of animal models. The method comprises the following steps: carrying out anaerobic culture on fusobacterium varium, giving the fusobacterium varium to a female C57 mouse through an intragastric administration way, continuously treating for 28 days, and inducing the female C57 mouse to have a phenotype that the number of implanted embryos is reduced and the expression of a vascular endothelial growth factor (VEGF) in a uterine tissue is reduced. According to the method, embryo implantation failure caused by intestinal flora imbalance is simulated through the'intestine-uterus axis' for the first time, a reliable animal model is provided for studying the causal relationship between flora and pregnancy failure, and the method has important scientific research and clinical application value.

The invention belongs to the technical field of biological agents, and particularly relates to composite IgY antibody freeze-dried powder for pet oral hygiene and a preparation method and application thereof. Oral bacteria such as prevotella intermedia, porphyromonas gingivalis, streptococcus mutans, actinomyces viscosus and fusobacterium nucleatum are selected in a targeted manner, the bacteria are used for preparing a composite IgY antibody, the composite IgY antibody is combined with the freeze-drying agent optimized by the invention, and the antibody freeze-dried powder is prepared by immunizing laying hens, so that the range of the bacteria is wider, and the immunogenicity of the laying hens is improved. The compound IgY antibody obtained by the prepared compound IgY antibody freeze-dried powder is high in activity, and the compound IgY antibody freeze-dried powder has good re-dissolvability, stability, affordability, simplicity and convenience, can maintain titer at-20 DEG C for more than two years, and is convenient to store, transport and popularize. Compared with the prior art, the composite IgY antibody freeze-dried powder aims at wider flora, can effectively resist canine oral malignant bacteria, and can be used as an additive to be added into oral health products such as toothpaste and mouth wash.

The invention discloses a preparation method of a gold (I) coordination compound and an application in antibiosis, a series of gold (I) coordination compounds have obvious inhibition effects on common oral germs such as staphylococcus aureus (S.a), porphyromonas gingivalis (P.g) and fusobacterium nucleatum (F.n), and the action effects of the gold (I) coordination compounds are better than those of common oral antibacterial drug chlorhexidine; the invention discloses improved preparation and purification methods of the gold (I) complexes, and the gold (I) complexes have good bacteriostatic activity on common oral germs.

Provided herein are pharmaceutical compositions, therapeutic combinations, devices and methods for treating, ameliorating, reversing, causing the remission of, and / or preventing (acting as a prophylaxis, or preventing the initiation of) an inflammatory bowel disorder (IBD) or inflammatory bowel disease (IBD), Ulcerative Colitis; Crohn's disease; J-pouch; fistulising Crohn's disease; a Colitis which can be microscopic, lymphocytic or collagenous; an eosinophilic colitis; indeterminate colitis; idiopathic colitis; diverticulosis and diverticulitis; relapsing diverticulitis; constipation associated inflammatory bowel disease and / or small intestinal bacterial overgrowth; Irritable Bowel Syndrome (IBS) with or without diarrhoea, constipation or pain predominant IBS; periodontitis; rheumatoid arthritis; respiratory infections, appendicitis, vascular disorders such as thrombophlebitis; bacteremia; osteomyelitis; septic shock; Alzheimer's disease; Lemierre syndrome (postanginal sepsis); colonic polyps or adenomas (optionally hyperplastic, adenomatous or serrated adenomas) or preventing the growth of colonic polyps or adenomas, bowl cancer, or metastases (optionally preventing the initiation or promotion of bowl cancer or metastasis); pharyngitis; otitis; sinusitis; and any disease, symptom or condition caused or exacerbated by a Fusobacteria (optionally, a F. nucleatum or F. varium) infection. In alternative embodiments, pharmaceutical compositions comprise rifaximin alone or in combination with other antibiotics or drugs.

The application discloses a new fusobacterium sp. LSCC04 and application thereof, the preservation number of the fusobacterium sp. LSCC04 is CCTCC NO:M 2025587, the fusobacterium sp. LSCC04 is successfully separated from a laryngeal carcinoma tissue, the strain has key technical properties such as stable growth, repeatable culture and clear storage condition, and solves the problem of the lack of related strains in the current laryngeal carcinoma microecological research field.

To provide a novel technique for removal of Fusobacterium and / or Streptococcus bacteria.SOLUTION: The foregoing problem is solved by a composition for removal of Fusobacterium and / or Streptococcus bacteria, containing platinum nanoparticles and / or electrolyzed water as an active ingredient.SELECTED DRAWING: None

The invention belongs to the technical field of biomedical nano-materials, and particularly relates to a preparation method and application of responsive nano-particles for targeted removal of fusobacterium nucleatum and a biological membrane of the fusobacterium nucleatum. The ERPNPs is formed by self-assembly of PEG (polyethylene glycol)-b-PCL (polycaprolactone), Pep-PAE (polycaprolactone)-b-PCL (polycaprolactone) and (PBA / PAE)-b-PCL, and the ERPNPs carry rifampicin and gallocatechin gallate together. The nano-system exposes FadA target peptide in an acidic tumor microenvironment, accurately recognizes Fn and synergistically sterilizes and disperses a biological membrane, so that an immunosuppression microenvironment is reversed, and the nano-system has an important application prospect in the development of anti-CRC drugs.

The invention belongs to the technical field of biology, and discloses an antibacterial peptide with activity of inhibiting human pathogenic bacteria as well as a preparation method and application of the antibacterial peptide. The antibacterial peptide or the salt thereof is disclosed for the first time, and the antibacterial peptide has a good antibacterial effect on common genital tract bacteria (such as staphylococcus aureus, gardnerella and candida albicans), oral pathogenic bacteria (such as fusobacterium nucleatum and streptococcus gordoni) and other pathogenic bacteria (such as escherichia coli, salmonella enteritidis and streptococcus suis); and the compound shows slight cytotoxicity to mammalian cells only at a high concentration.

The invention discloses a traditional Chinese medicine plaster for adjuvant therapy of clostridium difficile infection and reconstruction of intestinal flora balance and a preparation method thereof, and relates to the technical field of traditional Chinese medicine plasters, the traditional Chinese medicine plaster comprises a base material layer, an ointment and a protective layer, the ointment is prepared from effective components, a penetrant, an excipient, an adsorbent and deionized water; the effective components are prepared from rhizoma atractylodis macrocephalae volatile oil, cortex magnoliae officinalis volatile oil, folium artemisiae argyi volatile oil, a rhizoma coptidis extract, a herba taraxaci extract, a radix paeoniae alba extract and a poria cocos extract; according to the present invention, the accurate intervention of the intestinal microenvironment is achieved through the umbilical region targeting drug delivery and the combination of the dual mechanisms of the transdermal absorption and the acupoint stimulation, the drug action time is prolonged through the adsorbent porous slow-release structure, the flora balance is synchronously adjusted, the pathogenic bacterium proliferation is inhibited, and the limitation of the traditional oral administration or injection therapy is broken through; an efficient and convenient traditional Chinese medicine external treatment solution is provided for the drug-resistant clostridium difficile infection.

The invention relates to the technical field of molecular diagnosis and early screening of tumors, and particularly discloses a plasma circulating microbial marker for early screening of lung cancer and application of the plasma circulating microbial marker. The marker comprises the following components: staphylococcus aureus, fusobacterium nucleatum, klebsiella pneumoniae, alternaria simplex, legionella pneumophila, neisseria mucosa, Ralstonia petii, pasteurella multocida, and haemophilus parainfluenza (Haemophilus parainfluenza), and the marker comprises the following components: staphylococcus aureus, fusobacterium nucleatum, klebsiella pneumoniae, alternaria simplex, legionella pneumophila, neisseria mucosa, Ralstonia petii, pasteurella multocida, and Haemophilus parainfluenza (Haemophilus parainfluenza). According to the method, nine characteristic microbial markers are detected in combination with a low Pass WGS technology, a high-precision diagnosis model is constructed through a machine learning algorithm, the established diagnosis model has excellent stability and clinical applicability, efficient recognition of early lung cancer can be achieved, and the detection cost can be greatly reduced.

This invention discloses a dimetronidazole derivative or its pharmaceutical salt, with one of the following general structural formulas: The compounds of this invention exhibit good antibacterial activity and specificity against *Fusobacterium nucleatum* in in vitro antibacterial activity tests; derivative B2 has excellent in vitro antibacterial activity and selectivity against *Fusobacterium nucleatum*. In vivo studies using a mouse xenograft model of colorectal cancer have shown that compound B2, when used alone, has a certain antitumor effect against xenografts caused by *Fusobacterium nucleatum*. Furthermore, when compound B2 is administered in combination with a PD-1 antibody, it exhibits excellent in vivo antitumor activity and can effectively reverse the resistance of *Fusobacterium nucleatum*-infected colorectal cancer to PD-1 antibodies. The compounds of this invention can be used to treat colorectal cancer caused by *Fusobacterium nucleatum*, as well as tumor metastasis and drug resistance that occur during treatment.